Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Interesting Articles

| More

MNCs & their unlisted subsidiaries - A case of misplaced premium & forgotten risk

Posted On: 2020-05-16 12:30:44

Companies with MNC parentage trade at a substantial premium to their domestic counterparts. Most of these companies have been listed for many decades and have created huge wealth for the shareholders. But many MNCs operate in India through multiple entities which deprive the listed entity of full range of products and growth opportunities. The risk of that is now becoming increasingly apparent with increasing instances of new products being launched in the unlisted entities - bringing the underlying risks to the fore.

Author: N Balaji Vaidyanath - Crest Wealth Management
(Views are personal and not that of the company)

Long history of MNC wealth creation in India

Companies with foreign MNC parentage account for about 15% of the aggregate market capitalisation of listed companies in India. Most of them are of pre-1970's vintage, i.e., they were incorporated much before the 1973 FERA amendment and 1977 Janta Party government's diktat requiring foreign businesses to reduce parent stake below 40%. Many of these companies adapted well to the country and emerged the dominant players in sectors like FMCG, Auto and industrial manufacturing. As a result, they have created huge wealth for their investors. The fact that many of the MNCs are from the FMCG space - a sector which itself has been a huge wealth creator - has also contributed to their growing share of total listed market capitalisation. The Nifty MNC Index comprising of 30 companies is dominated by FMCG sector (51% weight), followed by Auto (14%), Pharma (9%) and Industrial Manufacturing (7%).

Rising valuation of MNC companies has also added to the wealth creation. MNCs enjoy a valuation premium on account of many factors that include: market leadership, management track record, lack of unnecessary diversifications (capital allocation), high dividend payouts as well as a superior perception on corporate governance.

MNC Index Performance BSE HC IDX and MNC Pharma Performance

Pharma MNCs have outperformed in the past 3-years

The overall Pharma Index has been drifting down over the past 5-years due to pricing pressures in the US market. Meanwhile, the MNC Pharma pack has been moving up since May-17 and has far outperformed the BSE Healthcare Index. We have aggregated the market capitalisation of 6 MNC pharma companies that form part of the 66 member BSE-HC Index for comparison in the exhibit above. These 6 MNC companies trade at an aggregate of 52x as compared to the BSE-HC Index P/E of 37x on trailing twelve month basis.

But listed Pharma MNCs fair poorly when it comes to revenue growth

MNC Pharma companies have started trading at FMCG like valuations. But when you compare the revenue growth, then only 1 company has had double digit revenue CAGR over both a 3-year and 5-year time frame. Earnings growth and cash flows are also relevant for valuations in which they score well. But unlike FMCG, domestic pharma products face stiffer regulatory controls and see erosion in prices at regular intervals under Drug Price Control Order.

MNC Pharma Revenue CAGR Large Fellow Subsidiaries

Misplaced Corporate Governance trust

Other promoter entities operating in competing or related businesses are a huge corporate governance red flag. But this hardly seems to be a bother for MNC companies with Indian entities contributing a very small share of their overall market cap. Many of them have multiple unlisted fellow subsidiaries operating in India with a couple of them having revenues larger than the listed entity. A couple of entities reported losses but that is due to the acquisition debt lying in the books on which it pays interest to the parent. Here are a few instances:

  • Abbott Healthcare Pvt. Ltd in addition to Pharma and Diagnostics gets 22% of revenue from nutritional products and houses the popular Pediasure and Ensure brands. After many failed attempts by multiple FMCG majors to break the duopoly of Complan and Horlicks/Boost in the malted food category, Abbott's brands have enjoyed relative success. The fruits of which are not enjoyed by the minority shareholders of the listed Abbott.
  • Pfizer Inc has two large unlisted entities acquired through global mergers including 2 large export oriented plants of Hospira; it earlier used to trade at a discount due to the issue.
  • AstraZeneca runs its global medicines development, business services, etc. via its unlisted entity.
  • Sanofi SA of France has a significant vaccines business that in India largely comes under Sanofi Pasteur India Pvt Ltd. It has other unlisted entities acquired in the past like Shantha Biotec and Genzyme (specialist in oncology).

These instances are not restricted to Pharma MNCs alone but are also seen in FMCG and Industrial sectors.

  • P&G's several popular brands such as Ariel, Tide, Pampers, Olay, H&S, and Pantene are housed in a separate larger unlisted entity.
  • Nestle launched its pet food business via Purina Petcare India Pvt Ltd. This is the first time Nestle has entered an entirely new business segment in India on its own since entering the market in 1912. Minority shareholders of Nestle India don't get to enjoy the benefits of a fast growing pet food category.
  • Colgate-Palmolive (parent) has entered the men's grooming category by picking a minority stake in Bombay Shaving Company.
  • Cummins has 7 other entities in India that make complementary products and components like turbo chargers, generators, filtration systems, lubricants but also competing products like CV and larger engines.

MNC premium is at risk in the post Covid19 world

In recent months, the Indian Pharma sector is back in the limelight as a prime beneficiary in the post Covid19 world of shifting supply chains. But unlike MNC engineering companies that use India as a base for exports, the growth prospects for listed MNC Pharma companies is limited as they focus solely on the domestic market. Moreover, even in the case of launching new products, vaccines or diagnostic kits for Covid19, these are likely to be brought in via the unlisted entities, letting the minority shareholders of listed MNCs continue to get the short end of the stick.

Having multiple operating companies though perfectly legal is a stark governance issue which the market has been ignoring for long, along with other issues like transfer of profits through opaque transfer pricing, higher royalties and fees charged by the parent company. As newer and high growth categories get launched via unlisted subsidiaries, the listed ones have to contend with the older and low growth categories thereby limiting their possible growth potential. Paying a huge premium for MNC Pharma similar to some FMCG companies, when these growth and corporate governance concerns could be catching attention, is a risky move.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

The Yamuna Syndicate Limited acquires 20,000 shares of ISGEC Heavy Engineering Ltd from open market

Decoding: Pledging of shares and upfront margins in the cash market!

SIDBI joins hands with Govt. of Rajasthan for the development of MSME ecosystem in the State

Are promoters using rights issue to increase their stake in the company?

All you want to know about Rights Entitlement

45% of the customers have taken moratorium PAN India; more observed in the northern region of the country: Finway

DISCOM dues balloon to ₹1.199 trillion

TNPL recommends dividend of Rs. 6 - Dividend Yield @ 5.45%

HUDCO - Rs. 2.35 dividend recommended - Dividend Yield @ 7.01%

PTC India Ltd - Rs. 5.50 dividend recommended - Dividend Yield @ 11.46%

PNB Gilts Ltd - Rs. 3 dividend recommended - Dividend Yield @ 8.57%

How to apply for Rights Issue of Arvind Fashions Limited?

How to apply for Rights Issue of Aditya Birla Fashion and Retail Limited?

An insight on Aarti Surfactants Limited

Covid-19 and its impact on businesses

Nifty Gained 8% in the June Series, Bank Nifty Surged 12%-Highest Since March 19 - HDFC Securities

IMF Growth Revision for India - Acuité Ratings & Research

Co-operative Banks - RBI Supervision - Acuité Ratings & Research

HDFC Securities views on relaxations announced by SEBI

India can reduce China trade deficit by over $8 billion in FY21-22 - Acuité Ratings & Research

How can investors preserve their wealth during times of crisis

JM Financial Yield Enhancer (Distressed Opportunity) Fund I raises Rs.160 crore in its first close

Samco Securities launches BTPT - Buy Today, Pay In Two days for Investors Buying Stocks

No data breach of BHIM app: Report

India's sovereign rating downgrade by Moody's - Acuité Ratings & Research

Banking Sector Credit Trends - Unusual trends - HDFC Securities

Rollover Report for May - June 2020: Angel Broking

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research on Q4 GDP

Mr. Dhiraj Relli views on GDP Numbers - HDFC Securities

Banking Sector Update - NIM compression on the cards - HDFC Securities

May series ends with a bang: Angel Broking

May 2020 F&O Series Expiry - Mr. Nandish Shah, Technical Research Analyst, HDFC Securities

Views on Impact of Locusts Attack on Agriculture - Acuité Ratings & Research

ICAI establishes Center for Audit Quality

Bharti Telecom raised over Rs. 8433 crores through Accelerated Book-build offering of equity shares of Bharti Airtel

SATYA MicroCapital raises INR 105 crore equity funding from Japan-based Gojo & Company Inc.

Mr. Rajnish Kumar, Chairman, SBI & IBA on the announcements made by RBI today

Views of Mr. Umesh Revankar, MD and CEO, Shriram Transport Finance on RBI announcement

Views of Mr. George Alexander Muthoot, MD, Muthoot Finance on RBI announcement today

Views of Ms. Anagha Deodhar - Economist, ICICI Securities on the RBI announcement today

Views on RBI Policy announcement today - Federal Bank

RBI Monetary Policy (May 2020) by Shanti Ekambaram, Group President - Consumer Banking, Kotak Mahindra Bank

Religare Finvest Ltd. on today's monetary policy by RBI

RBI monetary policy announcement - Mr. Jyoti Roy, DVP Equity Strategist, Angel Broking Ltd

RBI's proactive measure will help revive economy: Dr.Niranjan Hiranandani

Mr. Dhiraj Relli views on today's announcement made by RBI

Views of Mr. R K Gurumurthy, Head - Treasury, Lakshmi Vilas Bank on the RBI announcement today

Suvodeep Rakshit, Vice President & Sr. Economist, Kotak Institutional Equities on RBI announcement

Suman Chowdhury, Chief Analytical Officer at Acuité Ratings & Research, on today's RBI announcement

General Insurance Sector Update - GDPI continues to decline due to Lockdown - HDFC Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020